Dare Bioscience, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Sabrina Martucci Johnson
- Full Time Employees
- 23
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3655 Nobel Drive San Diego CA United States of America 92122
- IPO Date
- Apr 10, 2014
- CIK
- 0001401914
- Website
- darebioscience.com
- Similar Companies
- Business
- Daré Bioscience, Inc. (Nasdaq: DARE) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for women's health conditions. The company advances a diversified portfolio of proprietary product candidates targeting unmet needs in women's reproductive health, sexual health, and vaginal health; key programs include Ovaprene, a hormone-free, on-demand, monthly-use intravaginal ring for contraception currently in Phase 3 clinical development, Seysara for treatment of acne vulgaris in adult women, and bivosiran for potential use in endometriosis-associated pain, among others. Daré operates primarily in the United States with clinical trials and partnerships extending to global markets, and maintains its headquarters in San Diego, California, where it was founded in 2007 following the spin-off from Biosite Inc. The company's core offerings encompass preclinical and clinical-stage therapeutics delivered via novel drug delivery platforms such as silicone rings, gels, films, and mini-tablets designed for non-systemic or localized administration to minimize side effects. Daré provides research and development services through strategic collaborations with leading contract manufacturers and research organizations, serving healthcare providers, patients, and pharmaceutical partners in the women's health sector. Subsidiaries include Daré NewCo, LLC, which holds certain intellectual property assets. In the last two years, Daré Bioscience has expanded its pipeline through key strategic advancements, including the initiation of the Phase 3 AMagine trial for Ovaprene in 2023 with enrollment completion targeted for late 2025, and positive interim data from earlier studies supporting regulatory progress. The company secured a $15 million non-dilutive funding commitment from the U.S. Biomedical Advanced Research and Development Authority (BARDA) in 2024 to support women's health initiatives, alongside partnerships with Quotient Sciences for manufacturing scale-up and laboratoirés Genevir for gene silencing technologies in gynecology. These developments reflect Daré's shift toward late-stage commercialization readiness, with plans for potential U.S. FDA submissions by 2026 and international expansion into Europe and Asia.
Company News
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities
Contrasting RYTHM (NASDAQ:RYM) & Dare Bioscience (NASDAQ:DARE)
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
Daré Bioscience's Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society
Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List
Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates
Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances
Daré Bioscience, Inc. (DARE) Discusses Portfolio Advancements and Therapeutic Solutions for Women's Health Transcript
Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercialization Highlights on Virtual Bus Tour Transcript
Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx